Get the Stockscreener App
3.83
10.06%
0.35
After Hours:
3.88
0.05
+1.31%
Envveno Medical Corporation stock is traded at $3.83, with a volume of 668.30K.
It is up +10.06% in the last 24 hours and up +9.74% over the past month.
enVVeno Medical Corp is a late clinical-stage medical device company focused on advancing bioprosthetic (tissue-based) solutions to improve the standard of care for treating venous disease. The company's product, VenoValve, is a surgical replacement venous valve that is currently being evaluated in a U.S. pivotal study. The company is also developing a second product called enVVe, which is a non-surgical, transcatheter-based replacement venous valve. Both the products are designed to act as one-way valves to help assist in propelling blood up the veins of the leg, and back to the heart and lungs. The company has determined that it currently operates in a single segment, Medical Device development, located in a single geographic location, the United States.
See More
Previous Close:
$3.48
Open:
$3.58
24h Volume:
668.30K
Relative Volume:
7.47
Market Cap:
$63.30M
Revenue:
-
Net Income/Loss:
$-24.05M
P/E Ratio:
-1.7814
EPS:
-2.15
Net Cash Flow:
$-17.78M
1W Performance:
+6.09%
1M Performance:
+9.74%
6M Performance:
+23.55%
1Y Performance:
-21.68%
1-Day Range:
$3.56
$4.60
1-Week Range:
$3.44
$4.60
52-Week Range:
$2.0278
$6.48
Envveno Medical Corporation Stock (NVNO) Company Profile
Name
Envveno Medical Corporation
Sector
Industry
Phone
949-261-2900
Address
70 DOPPLER, IRVINE
Compare NVNO with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
NVNO
Envveno Medical Corporation
|
3.83 | 63.30M | 0 | -24.05M | -17.78M | -2.15 |
|
ABT
Abbott Laboratories
|
133.58 | 232.41B | 42.34B | 13.50B | 6.66B | 7.71 |
|
BSX
Boston Scientific Corp
|
102.09 | 155.73B | 17.55B | 2.03B | 2.72B | 1.37 |
|
SYK
Stryker Corp
|
383.89 | 146.23B | 23.22B | 2.86B | 3.58B | 7.40 |
|
MDT
Medtronic Plc
|
87.44 | 106.37B | 33.54B | 4.66B | 5.19B | 3.62 |
|
EW
Edwards Lifesciences Corp
|
77.52 | 45.88B | 5.54B | 4.18B | 623.10M | 7.00 |
Envveno Medical Corporation Stock (NVNO) Latest News
Positive Interim 2-Year Data from enVVeno Medical's VenoValve Pivotal Study to be Presented Today at the Society for Vascular Surgery (SVS) 2025 Vascular Annual Meeting - The Oklahoman
enVVeno Medical (NVNO) Shares Update on Promising Two-Year VenoV - GuruFocus
enVVeno Medical (NVNO) Shares Update on Promising Two-Year VenoValve Trial Results | NVNO Stock News - GuruFocus
Positive Interim 2-Year Data from enVVeno Medical's VenoValve Pi - GuruFocus
enVVeno Medical (NVNO) Showcases Promising Two-Year Data for Ven - GuruFocus
enVVeno Medical announces two-year data from VenoValve pivotal study - TipRanks
enVVeno Medical announces interim two-year follow-up data on VenoValve trial - TipRanks
enVVeno Medical Corporation (NASDAQ:NVNO) Short Interest Up 19.4% in May - Defense World
NVNBWForm FWPFiling under Securities Act Rules 163/433 of free writing prospectuses - mx.advfn.com
Northern Trust Corp Raises Holdings in enVVeno Medical Corporation (NASDAQ:NVNO) - Defense World
enVVeno Medical surges 70% following InvestingPro’s Fair Value signal By Investing.com - Investing.com
enVVeno Medical appoints Jennifer Bright as financial chief - MSN
enVVeno Medical Appoints New Chief Financial Officer - TipRanks
enVVeno Medical appoints new CFO amid growth phase By Investing.com - Investing.com South Africa
EnVVeno Medical Names Jennifer Bright as CFO - Orange County Business Journal
enVVeno Medical (NVNO) Appoints New CFO Jennifer Bright | NVNO Stock News - GuruFocus
enVVeno Medical (NVNO) Appoints New CFO, Jennifer Bright | NVNO Stock News - GuruFocus
enVVeno Medical (NVNO) Appoints New CFO Jennifer Bright | NVNO S - GuruFocus
enVVeno Medical appoints Jennifer Bright as CFO - TipRanks
EnVVeno Medical Names Jennifer Bright CFO - marketscreener.com
enVVeno Medical appoints new CFO amid growth phase - Investing.com
enVVeno Medical Appoints Jennifer Bright as Chief Financial Officer | NVNO Stock News - GuruFocus
enVVeno Medical Appoints Jennifer Bright as Chief Financial Officer - ACCESS Newswire
Dimensional Fund Advisors LP Decreases Stake in enVVeno Medical Corporation (NASDAQ:NVNO) - Defense World
EnVVeno has first-in-human valve data, expects FDA decision this year - MassDevice
NVNO's VenoValve Shows Promising Three-Year Outcomes in Publishe - GuruFocus
Three-Year VenoValve(R) First-in-Human Trial Data Published in t - GuruFocus
Three-year VenoValve first-in-human trial data show high patency rate - Venous News
enVVeno Medical (NVNO) Reveals Promising Three-Year VenoValve Ou - GuruFocus
enVVeno Medical publishes three-year VenoValve data - TipRanks
enVVeno Medical (NVNO) Reveals Promising Three-Year VenoValve Outcomes | NVNO Stock News - GuruFocus
Three-Year VenoValve(R) First-in-Human Trial Data Published in the Annals of Vascular Surgery - ACCESS Newswire
NVNO's VenoValve Shows Promising Three-Year Outcomes in Published Study | NVNO Stock News - GuruFocus
Geode Capital Management LLC Increases Stake in enVVeno Medical Corporation (NASDAQ:NVNO) - Defense World
NVNO: Financial Position Supports Key Developments Ahead | NVNO Stock News - GuruFocus
enVVeno Medical (NVNO) Eyes Commercial Transition with VenoValve - GuruFocus
enVVeno Medical (NVNO) Eyes Commercial Transition with VenoValve Progress | NVNO Stock News - GuruFocus
enVVeno Medical Reports First Quarter 2025 Financial Results and - GuruFocus
Press Release Distribution & PR Platform - ACCESS Newswire
enVVeno Medical Reports First Quarter 2025 Financial Results and Reiterates Progress Toward VenoValve FDA Decision Expected in 2H24 - Corsicana Daily Sun
enVVeno Medical Reports Strong Q1 Financials with $38.9M War Chest for VenoValve FDA Launch - Stock Titan
enVVeno Medical Reports First Quarter 2025 Financial Results and Reiterates Progress Toward VenoValve FDA Decision Expected in 2H24 | NVNO Stock News - GuruFocus
enVVeno Medical Participates in the Virtual Investor “Top 5 for ‘25” On-Demand Conference - ACCESS Newswire
JPMorgan Chase & Co. Buys New Shares in enVVeno Medical Corporation (NASDAQ:NVNO) - Defense World
enVVeno Medical Corporation Announces Pricing of $15.0 Million Public Offering - ACCESS Newswire
VenoValve to be Featured During Presentation at the 47th Annual Charing Cross Symposium | NVNO Stock News - GuruFocus
VenoValve to be Featured During Presentation at the 47th Annual Charing Cross Symposium - Weatherford Democrat
Envveno Medical Corporation Stock (NVNO) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.56%
1.70%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):